Fortrea Holdings Inc. (FTRE)
Conducts drug and medical device testing for pharmaceutical companies from research through patient recruitment.
$20.70+0.08%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+279.1%
The outlook
Fortrea is trading near the top of its 52-week range and above both its 50- and 200-day moving averages, showing upward momentum. However, analysts on average have set price targets about 17% below the current price, suggesting some caution. The overall analyst lean is bullish, though the gap between current valuation and targets indicates mixed near-term sentiment.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range97% of the way from its 52-week low to high
Price targetAvg target -17% vs current price
Analyst price target
~12-month · 11 analysts$17.25average target-16.6% vs now
Now $20.70
Low $11.00High $20.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.96B
52-wk high
$21.12
52-wk low
$5.27
50-day avg
$16.58
200-day avg
$13.50
Trailing P/E
—